Mirum Pharmaceuticals Inc (MIRM) is a biopharmaceutical company focused on developing and commercializing therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is a small molecule inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that is currently in development for the treatment of progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome.
Maralixibat has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of pruritus in patients with Alagille syndrome and is currently in Phase 3 clinical trials for the treatment of PFIC. In addition to maralixibat, Mirum is also developing two other product candidates, volixibat and MIRM-401, both of which are in preclinical development for various liver diseases.
Mirum was founded in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals Inc (MIRM) is a biopharmaceutical company focused on developing and commercializing therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is a small molecule inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that is currently in development for the treatment of progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome.